Effect of Celery Seed (Apium graveolens L.) Administration on the Components of Metabolic Syndrome, Insulin Sensitivity, and Insulin Secretion: A Clinical Trial
Open Access
- 7 January 2026
- journal article
- research article
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (1) , 110
Abstract
Background/Objectives: Metabolic syndrome (MetS) is a group of cardiometabolic risk factors whose current management relies on lifestyle changes and pharmacological interventions, frequently involving multiple medications. Therefore, the demand for therapies capable of delivering comprehensive management of MetS is increasing. In this context, nutraceuticals such as celery seed have attracted increasing scientific interest. This study aimed to evaluate the effect of celery seed (Apium graveolens L.) administration on the components of MetS, insulin sensitivity, and insulin secretion. Methods: A randomized, double-blind, placebo-controlled clinical trial was carried out in 28 patients with MetS. Fourteen patients randomly received celery seed (150 mg/day) for 12 weeks, and 14 subjects received a placebo. Clinical and laboratory determinations were evaluated at baseline and the end of the study. Results: After celery seed administration, patients showed a significant decrease in their systolic blood pressure (SBP) (121.0 ± 9.7 mmHg vs. 115.7 ± 12.8 mmHg, p = 0.005), diastolic blood pressure (DBP) (82.2 ± 5.9 mmHg vs. 78.5 ± 8.6 mmHg, p = 0.013), triglycerides (TG) (2.3 ± 0.9 mmol/L vs. 1.8 ± 0.6 mmol/L, p = 0.016), very low-density lipoprotein (VLDL) (0.4 ± 0.1 mmol/L vs. 0.3 ± 0.1 mmol/L, p = 0.016) and uric acid (297.4 ± 53.5 µmol/L vs. 261.7 ± 53.5 µmol/L, p = 0.009). Insulin sensitivity and insulin secretion showed no statistically significant differences in the celery seed group. Conclusions: Celery seed administration significantly reduced SBP, DBP, TG, VLDL, and uric acid. The protocol was registered at ClinicalTrials.gov with the identifier NCT06061926.Keywords
This publication has 40 references indexed in Scilit:
- The effect of celery (Apium graveolens) powder on cardiometabolic factors in overweight/obese individuals with type 2 diabetes mellitus: A pilot randomized, double‐blinded, placebo‐controlled clinical trialFood Science & Nutrition, 2023
- Mineral Content Variation in Leaves, Stalks, and Seeds of Celery (Apium graveolens L.) GenotypesBiological Trace Element Research, 2022
- Effect of celery (Apium graveolens) seed extract on hypertension: A randomized, triple‐blind, placebo‐controlled, cross‐over, clinical trialPhytotherapy Research, 2022
- How Much Lowering of Blood Pressure Is Required to Prevent Cardiovascular Disease in Patients With and Without Previous Cardiovascular Disease?Current Cardiology Reports, 2022
- Triglycerides and risk of atherosclerotic cardiovascular disease: An updateArchives of Cardiovascular Diseases, 2021
- Beneficial effects of celery (Apium graveolens) on metabolic syndrome: A review of the existing evidencesPhytotherapy Research, 2019
- Rationale and design of REDUCE‐IT: Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention TrialClinical Cardiology, 2017
- Evaluation of mechanism for antihypertensive and vasorelaxant effects of hexanic and hydroalcoholic extracts of celery seed in normotensive and hypertensive ratsRevista Brasileira de Farmacognosia, 2016
- Low-dose diet supplement of a natural flavonoid, luteolin, ameliorates diet-induced obesity and insulin resistance in miceMolecular Nutrition & Food Research, 2014
- The Metabolic Syndrome and Cardiovascular RiskJACC, 2010